CEO SUMMARY: Commercial laboratories are recognizing declines in the market value of their assets. LabCorp has yet to do the same. Taken cumulatively, these write-downs demonstrate the sizable revenue erosion that large commercial laboratories experienced during the past three years. Soon it will be LabCorp’s turn to address this issue. MORE THAN $550 MILLION of …
Where’s The Write-down ? LabCorp Faces Key Decision Read More »
This post is only available to members.